SCHEMBL700602

SCHEMBL700602

Cc1nc2ccc(C(=O)N3CCN(C)CC3)cn2c1-c1ccnc(Nc2ccc(C(=O)Nc3ccccc3N)cc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 14/20 0.60
JAK2 O60674 2/20 0.52
CDK2 P24941 3/20 0.49
CDK1 P06493 1/20 0.49
BRD4 O60885 2/20 0.48
JAK1 P23458 2/20 0.48
BTK Q06187 1/20 0.47
HDAC3 O15379 3/20 0.45
PDGFRB P09619 3/20 0.45
KDR P35968 3/20 0.45
HDAC4 P56524 3/20 0.45
HDAC7 Q8WUI4 3/20 0.45
HDAC2 Q92769 3/20 0.45
HDAC10 Q969S8 3/20 0.45
HDAC11 Q96DB2 3/20 0.45
HDAC8 Q9BY41 3/20 0.45
HDAC6 Q9UBN7 3/20 0.45
HDAC9 Q9UKV0 3/20 0.45
HDAC5 Q9UQL6 3/20 0.45
ABL1 P00519 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699851 0.90 HDAC1 (0.57) HDAC1JAK2CDK2CDK1BRD4
SCHEMBL7964300 0.88 HDAC1 (0.66) HDAC1JAK2CDK2HDAC3PDGFRB
SCHEMBL700985 0.87 CDK2 (0.55) HDAC1JAK2CDK2CDK1JAK1
SCHEMBL701831 0.87 HDAC1 (0.47) HDAC1JAK2BRD4JAK1BTK
SCHEMBL7964776 0.86 HDAC1 (0.65) HDAC1JAK2CDK2HDAC3PDGFRB
SCHEMBL702259 0.85 HDAC1 (0.65) HDAC1JAK2CDK2HDAC3PDGFRB
SCHEMBL699358 0.85 HDAC1 (0.80) HDAC1JAK2CDK2HDAC3PDGFRB
SCHEMBL12790437 0.85 HDAC1 (0.46) HDAC1CDK2BRD4JAK1HDAC3
SCHEMBL656639 0.85 HDAC1 (0.52) HDAC1JAK2CDK2BRD4JAK1
SCHEMBL700829 0.84 HDAC1 (0.64) HDAC1JAK2CDK2HDAC3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 HDAC1 1/4885JAK2 745/4885CDK2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.